Trials / Completed
CompletedNCT00132925
An Efficacy and Safety Evaluation of Nasacort AQ in Children Ages 2-5 Years With Perennial Allergic Rhinitis
An Efficacy and Safety Evaluation of Nasacort AQ 110 µg QD Children Ages 2-5 Years With Perennial Allergic Rhinitis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 460 (planned)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 2 Years – 5 Years
- Healthy volunteers
- Not accepted
Summary
The purposes of this study are: * To demonstrate the efficacy of once daily administration of Nasacort AQ 110 µg compared with placebo in children 2-5 years of age with perennial allergic rhinitis; and * To assess the safety of Nasacort AQ 110 µg in children 2-5 years of age.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Triamcinolone |
Timeline
- Start date
- 2003-11-01
- Completion
- 2006-02-01
- First posted
- 2005-08-22
- Last updated
- 2011-01-11
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00132925. Inclusion in this directory is not an endorsement.